Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 36Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Neoplasms 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Leukemia 6Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Pain 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Hematologic Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Sezary Syndrome 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hormone-Resistant Prostate Cancer × Prednisone × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡